Back to all papers

A proof of concept study of <sup>18</sup>F-FDG PET/CT patient-level radiomics identify refractory/relapsed diffuse large B-cell lymphoma.

Authors

Cui C,Cao J,Li Y,Jia B,Ma N,Li X,Liang M,Hou M,Zhang Y,Wang H,Wu Z

Affiliations (5)

  • Special Medical Research Institute of Shanxi Medical University, Taiyuan, China.
  • Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, China.
  • Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Shanxi Medical University, Taiyuan, China.
  • Special Medical Research Institute of Shanxi Medical University, Taiyuan, China. [email protected].
  • Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, China. [email protected].

Abstract

This study aimed to evaluate diffuse large B-cell lymphoma (DLBCL) patients who have refractory/relapsed disease and characterize the heterogeneity of DLBCL using patient-level radiomics analysis based on <sup>18</sup>F-FDG PET/CT. A total of 132 patients diagnosed with DLBCL who underwent <sup>18</sup>F-FDG PET/CT before receiving treatment were selected for the final study. Patient-level volumes of interests (VOI) were extracted from PET/CT images, and 328 radiomics features were extracted subsequently. 8 radiomics features were selected using the Least Absolute Shrinkage and Selection Operator (LASSO) algorithm to calculate the radiomics score (rad-score). Additionally, a total of 64 potential ML classifiers were generated based on 8 distinct supervised learning algorithms. The combined model that integrates rad-scores, clinical features and standard PET parameters demonstrates excellent performance; Specifically, ML models based on Naive Bayes have the greatest predicted values (AUC = 0.73). The patient-level radiomics features were subjected to unsupervised non-negative matrix factorization (NMF) clustering analysis to identify 3 radiomics subtypes. Cluster 1 exhibited a substantially higher prevalence of refractory/relapsed DLBCL compared to Clusters 2 and 3 (P < 0.05). Moreover, Cluster 1 showed a significantly higher frequency of advanced Ann Arbor stage, high international prognostic index, and bulk disease (all P < 0.05). In conclusion, Radiomics scores and radiomics subtypes derived from patient-level data offer significant predictive value and phenotypic information for patients with refractory/relapsed DLBCL.

Topics

Lymphoma, Large B-Cell, DiffusePositron Emission Tomography Computed TomographyFluorodeoxyglucose F18Journal Article

Ready to Sharpen Your Edge?

Join hundreds of your peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.